-
1Academic Journal
المؤلفون: L. V. Bolotina, A. L. Kornietskaya, A. A. Kachmazov, N. S. Prizova, A. A. Paichadze, T. V. Ustinova, T. I. Deshkina, S. F. Evdokimova, Л. В. Болотина, А. Л. Корниецкая, А. А. Качмазов, Н. С. Призова, А. А. Пайчадзе, Т. В. Устинова, Т. И. Дешкина, С. Ф. Евдокимова
المصدر: Meditsinskiy sovet = Medical Council; № 9 (2022); 179-184 ; Медицинский Совет; № 9 (2022); 179-184 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: герминальные мутации, PARP inhibitors, olaparib, HER2neu amplification, germline mutation, PARP-ингибиторы, олапариб, амплификация HER2neu
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6931/6228; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. https://doi.org/10.3322/caac.21551.; Litton J.K., Rugo H.S., Ettl J., Hurvitz SA., Goncalves A., Lee K.H. et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-763. https://doi.org/10.1056/NEJMoa1802905.; Robson M., Im S.A., Senkus E., Xu B., Domchek S.M., Masuda N. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533. https://doi.org/10.1056/NEJMoa1706450.; Malone K.E., Daling J.R., Doody D.R., Hsu L., Bernstein L., Coates R.J. et al. Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years. Cancer Res. 2006;66(16):8297-8308. https://doi.org/10.1158/0008-5472.CAN-06-0503.; Engel C., Fischer C. Breast Cancer Risks and Risk Prediction Models. Breast Care (Basel). 2015;10(1):7-12. https://doi.org/10.1159/000376600.; Antoniou A., Pharoah P.D.P., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L. et al. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. Am J Hum Genet. 2003;72(5):1117-1130. https://doi.org/10.1086/375033.; Chen S., Parmigiani G. Meta-Analysis of BRCA1 and BRCA2 Penetrance. J Clin Oncol. 2007;25(11):1329-1333. https://doi.org/10.1200/JCO.2006.09.1066.; Mavaddat N., Barrowdale D., Andrulis I.L., Domchek S.M., Eccles D., Nevanlinna H. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134-147. https://doi.org/10.1158/1055-9965.EPI-11-0775.; Levy-Lahad E., Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007;96(1):11-15. https://doi.org/10.1038/sj.bjc.6603535.; Wang X., Liu H., Maimaitiaili A., Zhao G., Li S., Lv Z. et al. Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer. Mol Genet Genomic Med. 2019;7(6):e677. https://doi.org/10.1002/mgg3.677.; Thompson D., Easton D. The Genetic Epidemiology of Breast Cancer Genes. J Mammary Gland Biol Neoplasia. 2004;9(3):221-236. https://doi.org/10.1023/B:JOMG.0000048770.90334.3b.; Foulkes W.D. Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. J Natl Cancer Inst. 2003;95(19):1482-1485. https://doi.org/-10.1093/jnci/djg050.; Ratnam K., Low J.A. Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology. Clin Cancer Res. 2007;13(5):1383-1388. https://doi.org/10.1158/1078-0432.CCR-06-2260.; Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol. 2008;8(4):363-369. https://doi.org/10.1016/j.coph.2008.06.016.; Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.J Clin Oncol. 2008;26(22):3785-3790. https://doi.org/10.1200/JCO.2008.16.0812.; Lord C.J., Ashworth A. PARP Inhibitors: The First Synthetic Lethal Targeted Therapy. Science. 2017;355(6330):1152-1158. https://doi.org/10.1126/science.aam7344.; Shukla M.A., Barrera A.G., Gruschkus S.K., Layman R.M., Murthy R.K., Arun B.K. Abstract PS4-31: Characteristics of HER2/neu positive breast cancer among patients with and without germline BRCAmutations. Cancer Res. 2021;81 (4_Suppl.):PS4-31. https://doi.org/10.1158/1538-7445.SABCS20-PS4-31; Evans D.G., Lalloo F., Howell S., Verhoe S., Woodward E.R., Howell A. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Res Treat. 2016;155(3):597-601. https://doi.org/10.1007/s10549-016-3697-z.; Garda-Parra J., Dalmases A., Morancho B., Arpí O., Menendez S., Sabbaghi M. et al. Poly (ADP-ribose) polymerase ihibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. Eur J Cancer. 2014;50(15):2725-2734. https://doi.org/10.1016/j.ejca.2014.07.004.; Oh K.S., Nam A.R., Bang J.H., Seo H.R., Kim J.M., Yoon J. et al. Abstract 1079: A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab-resistance in HER2-positive cancers. Cancer Res. 2021;81 (13_Suppl.):1079. https://doi.org/10.1158/1538-7445.AM2021-1079; Frenel J.S., Dalenc F., Pistilli B., de La Motte Rouge T., Levy C., Mouret--Reynier M.A. et al. 304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial. Ann Oncol. 2020;31:S364. https://doi.org/10.1016/j.annonc.2020.08.406; Zundelevich A., Dadiani M., Kahana-Edwin S., Itay A., Sella T., Gadot M. et al. Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. 2020 г. Breast Cancer Res. 2020;22(1):28. https://doi.org/10.1186/s13058-020-01265-y.; Moeder C.B., Giltnane J.M., Harigopal M., Molinaro A., Robinson A., Gelmon K. et al. Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray - Based Assessment of Outcome. J Clin Oncol. 2007;25(34):5418-5425. https://doi.org/10.1200/JCO.2007.12.8033.; Seol H. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012;25(7): 938-948. https://doi.org/10.1038/modpathol.2012.36.; Lee H.J., Seo A.N., Kim E.J., Jang M.H., Suh K.J., Ryu H.S. et al. HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer. Am J Clin Pathol. 2014;142(6):755-766. https://doi.org/10.1309/AJCPIRL4GUVGK3YX.; Lee K., Jang M.H., Chung Y.R., Lee Y., Kang E., Kim S.W. et al. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype. Hum Pathol. 2017;61:111-120. https://doi.org/10.1016/j.humpath.2016.12.004.; Hanna W.M., Ruschoff J., Bilous M., Coudry R.A., Dowsett M., Osamura R.Y. et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014;27(1):4-18. https://doi.org/10.1038/modpathol.2013.103.; Ahn S., Kim H.J., Kim M., Chung Y.R., Kang E., Kim E.K. et al. Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. Cancer Res Treat. 2018;50(4):1418-1432. https://doi.org/10.4143/crt.2017.552.; De La Cruz L.M., Harhay M.O., Zhang P., Ugras S. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How?: IHC Profile and Neoadjuvant Chemotherapy. Ann Surg Oncol. 2018;25(12):3535-3540. https://doi.org/10.1245/s10434-018-6608-1.; Schrijver W.A.M.E., Suijkerbuijk K.P.M., van Gils C.H., van der Wall E., Moelans C.B., van Diest P.J. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018;110(6):568-580. https://doi.org/10.1093/jnci/djx273.; https://www.med-sovet.pro/jour/article/view/6931